Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06680206 · ClinicalTrials.gov registry record
Comparison of Patient-reported Outcomes for Rimegepant and Triptans in the 2023 US National Health and Wellness Survey
A clinical trial, sponsored by Pfizer.
- Completed
- Registry status
- 1,395
- Enrollment target
NCT06680206 is a clinical trial that has completed, run by Pfizer. The registered enrollment target is 1,395 participants.
The verdict
NCT06680206 has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- 1,395 participants
- Enrollment target
Study Summary
This is a cross-sectional study using the cross-sectional 2023 National Health and Wellness Survey (NHWS) data from the US, with a large and nationally representative population (N=75,007). All data from the NHWS are reported by respondents, who are recruited through an existing, general-purpose, web-based, consumer panel via opt-in e-mails, co-registration with panel partners, e-newsletter campaigns, banner placements, and affiliate networks. All respondents explicitly agree to be a panel member, register with the panel through a unique e-mail address, and complete an in-depth demographic registration profile. This analysis will focus on respondents who self-report having migraine diagnosed by a physician. Individuals who use rimegepant for acute treatment of migraine will be compared with those who use triptans for acute treatment of migraine. Outcomes of interest include treatment satisfaction, healthcare resource utilization (HCRU), quality of life (QoL), work productivity loss, and migraine-specific disability outcomes. Inverse probability of treatment weighting (IPTW) will be used to adjust for differences that may exist between rimegepant and triptan users prior to comparing outcomes.
Interventions
- DRUG Rimegepant
- DRUG Triptans
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,395 participants |
| Start Date | 2024-10-10 |
| Est. Completion | 2024-11-20 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06680206
The ClinicalTrials.gov registry entry for NCT06680206 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 1,395 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Rimegepant is the first listed.
NCT06680206 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06680206 about?
NCT06680206 is a clinical study titled "Comparison of Patient-reported Outcomes for Rimegepant and Triptans in the 2023 US National Health and Wellness Survey". This is a cross-sectional study using the cross-sectional 2023 National Health and Wellness Survey (NHWS) data from the US, with a large and nationally representative population (N=75,007). All data from the NHWS are reported by respondents, who are recruited through an existing, general-purpose, w...
What is the current status of trial NCT06680206?
This trial is currently completed. The enrollment target is 1,395 participants. The study started on 2024-10-10. Estimated completion is 2024-11-20.
What interventions are being tested in trial NCT06680206?
The interventions under investigation include: Rimegepant (DRUG), Triptans (DRUG).
Who is sponsoring clinical trial NCT06680206?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.